Policy & Compounding
Lifestyle Habits Stacked Against Peptides: Which Makes You Live Longer
Most peptides in a wellness stack have zero human trials. See what the research shows, and the 12-year gap five basic habits produced.
Policy & Compounding
FDA decisions, state bills and shortages, and the compounding pharmacies in the middle of them.
Policy & Compounding
1 in 18 Black Market Peptide Vials Matched Its Label
An Australian lab tested 18 vials sold as retatrutide. One matched its label. See what the dosing errors were and why a purity test proves little.
Policy & Compounding
People Are Injecting 'Barbie Peptides' to Tan. Here's What the FDA Actually Says About Melanotan
Melanotan II is sold as a tanning shortcut. See the FDA's own safety language, the published case reports, and where the 2026 peptide review stands.
Policy & Compounding
Why Isn't My Pharmacy Licensed in My State? What to Check
Your vial says one company but your provider lists another pharmacy. See why, what an outsourcing facility is, and how to check your state license.
Policy & Compounding
FDA Panel Backs 6 Peptides for Compounding: What's Next
An FDA panel backed 6 of 7 peptides for the compounding list. See the votes, what each was proposed to treat, and what has to happen next.
Policy & Compounding
The FDA Peptide Panel: Could These 7 Be Compounded?
An FDA panel meets July 23-24 to weigh whether 7 peptides can be compounded. See which peptides, what the FDA recommends, and what it means.
More in Policy & Compounding
- Cost & Coverage
Who's Using GLP-1s Now? The 2026 Numbers, Explained
GLP-1 use hit a new high in 2026: about 11% of US adults now take one. See who is using them, the brand vs compounded split, and what it means.
- Policy & Compounding
Retatrutide Grey Market: What's Legal, What's Risky?
Retatrutide is not FDA approved. Learn why buying it online or in stores is not legal or safe, and how licensed pharmacy compounding is different.
%2520doing%2520lap%2520swimming%2520in%2520a%2520long%2520outdoor%2520pool.png&w=3840&q=75)
- Policy & Compounding
The 2026 FDA Peptide Reclassification: What It Means for You
The FDA moved 12 peptides off its restricted list and reviews 7 in July 2026. See what it could mean for compounding, your GLP-1, and peptide safety.
- Medications
Additives in Compounded GLP-1s: What They Do and Allergy Risks
B12, B6, niacinamide, glycine, benzyl alcohol: see what each GLP-1 additive does, the allergy risks, and how to search providers by additive.
- Medications
CagriSema and the October 2026 FDA Decision: What to Know
CagriSema is under FDA review with a decision expected in 2026. See what the trials showed and how it compares to Wegovy and Zepbound.
- Medications
Retatrutide Before FDA Approval: What You Should Know
Retatrutide is not FDA approved, but some clinics sell it anyway. See what the science shows and why approval status matters for you.
